Q2 EPS Estimate for Larimar Therapeutics Raised by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Analysts at William Blair boosted their Q2 2025 earnings per share estimates for Larimar Therapeutics in a research report issued on Wednesday, April 30th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.50) per share for the quarter, up from their […]

Leave a Reply

Your email address will not be published.

Previous post Q2 EPS Estimates for El Pollo Loco Cut by William Blair
Next post Telsey Advisory Group Has Negative View of HVT Q2 Earnings